Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.3752W HIGH $15.89
Volume
39.58 K
Value Traded
12.70 M
Short % Float
6.2%
-2.21%Week
-5.8%1 Month
+8.08%3 Month
+41.72%6 Month
-44.83%5 Year
-38.54%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.08 B
EPS (TTM)
0.80
P/E Ratio
16.10
Ent. Value
1.30 B
Total Shares
84.09 M
Float Shares
47.25 M
Insiders
30.83%
Institutions
60.05%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BVS Catalyst Timeline
Dated clinical, regulatory and corporate events for Bioventus Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bioventus Inc.
154Total events
0Upcoming
45Tier-1 (high impact)
2020 to 2026Coverage
Event history 50
▲Debt Royalty FinancingCorporate
Bioventus makes $20M discretionary principal prepayment on term loan
◆Oral PresentationPresentation
Bioventus to present at Goldman Sachs 47th Annual Global Healthcare Conference
▲Quarterly UpdateCorporate
Bioventus reports Q4 2025 revenue of $157.9M, GAAP EPS $0.21, non-GAAP EPS $0.24
▲Product LaunchStimTrialApprovedPost-Market
Full commercial launch of StimTrial peripheral nerve stimulation product
chronic painsource ↗
▲Product LaunchTalisMannApprovedPost-Market
Full commercial launch of TalisMann peripheral nerve stimulation product
chronic painsource ↗
▲Management ChangeCorporate
Addition of Megan Rosengarten as SVP and GM of Peripheral Nerve Stimulation
◆Oral PresentationPresentation
Bioventus CEO presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Runway Guidance UpdateCorporate
FY2026 guidance: net sales $600-610M, adjusted EPS $0.73-0.77, cash from ops $82-87M
▲Product LaunchTalisMannApprovedPost-Market
Broader rollout of TalisMann
chronic pain managementsource ↗
▲Product LaunchStimTrialApprovedPost-Market
Broader rollout of StimTrial
chronic pain managementsource ↗
●Quarterly UpdateCorporate
Reiterated full year 2025 guidance: revenue $560M-$570M, Adj. EBITDA $112M-$116M, Non-GAAP EPS $0.64-$0.68
◆Oral PresentationPresentation
Bioventus President and CEO to present at Piper Sandler Healthcare Conference
▲Product LaunchPost-Market
Launch of XCELL PRP System in U.S. market
Orthopedic and Sports Medicinesource ↗
▲Product LaunchStimTrialApprovedPost-Market
Limited launch of StimTrial for chronic pain
Chronic painsource ↗
▲Product LaunchTalisMannApprovedPost-Market
Limited launch of TalisMann for chronic pain
Chronic painsource ↗
◆Oral PresentationPresentation
Bioventus to present at Morgan Stanley Global Healthcare Conference
◆Oral PresentationPresentation
Bioventus to present at Canaccord Genuity 45th Annual Global Growth Conference
▲FDA ApprovalTalisMannApprovedFDA Decision
FDA 510(k) clearance for TalisMann
chronic pain managementsource ↗
▲FDA ApprovalStimTrialApprovedFDA Decision
FDA 510(k) clearance for StimTrial
chronic pain managementsource ↗
▲Product LaunchTalisMannApprovedPost-Market
Limited commercial release of TalisMann in select U.S. markets
chronic pain managementsource ↗
▲Product LaunchStimTrialApprovedPost-Market
Limited commercial release of StimTrial in select U.S. markets
chronic pain managementsource ↗
▲Partnership / LicenseCorporate
Entered into distribution agreement with APEX Biologix for XCELL PRP system in the US
Pain Treatmentssource ↗
●Management ChangeCorporate
Added Dave Venner as SVP & GM of Surgical Solutions and Jeff Ciardi as VP for Strategic Accounts and Market Access
▲AcquisitionCorporate
Divestiture of Advanced Rehabilitation business to Accelmed Partners completed
●Timing GuidancePresentation
Reiterated full year 2025 guidance: net sales $560M-$570M, Adj EBITDA $112M-$116M, Non-GAAP EPS $0.64-$0.68
◆AcquisitionCorporate
Bioventus signs definitive agreement to sell Advanced Rehabilitation business to Accelmed Partners
◆Oral PresentationPresentation
Bioventus to present at Canaccord Genuity 44th Annual Global Growth Conference
▲Other Regulator MilestoneEx-US Regulatory
Obtained EU MDR Certification for Exogen Bone Stimulation System
bone healingsource ↗
◆Management ChangeCorporate
Robert Claypoole appointed President and CEO, effective January 10, 2024
▲Product LaunchDUROLANEPost-Market
Nationwide contract with Aetna Medicare Advantage plans for DUROLANE
knee osteoarthritissource ↗
Past FDA Catalysts and PDUFA Decisions
How BVS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D37 / 100
Pipeline Score
$150M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 47%
Micro Cap(rank 310 of 658)
Percentile Rank
Bioventus Inc. faces pipeline headwinds (37/100), with $374M risk-adjusted pipeline value, led by PTP-001 in Osteoarthritis, Knee (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PTP-001 Monoclonal antibodyNCT05100225 | Osteoarthritis, Knee | Phase 2 | ACTIVE NOT_RECRUITING | 210 | Nov 30, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every BVS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bartholdson John A.Director, 10% Owner | Option | 32,282 111,902 held | $0.00 | 06/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BVS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Redmile Group, LLC | 0.1 % (-75 %) | 1.40 M | 535.95 K | -58.75% ( -763.19 K) |
BVS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BVS ranks across every disease it competes in
Competitive Position is a premium feature
See how BVS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBVS News
BVS▲ +13.7%on this news
Bioventus Reports Second Quarter Financial Results
Bioventus reported a strong Q2 2026 with a 4% revenue increase to $153.2 million and significant growth in GAAP earnings per diluted share, rising to $0.47. The company reaffirmed its financial guidance for 2026, indicating confidence in its growth strategy. However, there were declines in certain segments, including Surgical Solutions and Restorative Therapies, which could pose challenges ahead.
Read more →BVSBioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026
Bioventus Inc. will report its financial results for the second quarter of fiscal year 2026 on August 5, 2026. The announcement includes a conference call scheduled for 8:30 a.m. Eastern Time to discuss the results and provide a business update. The call will be accessible via phone and a live webcast.
Read more →BVSBioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
Bioventus Inc. will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Mark Singleton, the company's Senior Vice-President and CFO, will participate in a fireside chat. A live webcast of the event will be available on the company's website, allowing for broader audience engagement.
Read more →BVSBioventus Reports First Quarter Financial Results
Bioventus Inc. reported a strong start to 2026 with a 7% increase in Q1 revenue, totaling $132.1 million. The company achieved positive net income of $3.1 million, a significant turnaround from a loss in the prior year. Bioventus raised its financial guidance for the year, reflecting confidence in continued growth across its product portfolio.
Read more →BVSBioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026
Bioventus Inc. will report its financial results for the first quarter of fiscal year 2026 on May 6, 2026. The report will be released before the market opens, followed by a conference call at 8:30 a.m. Eastern Time to discuss the results and provide a business update. A live webcast will also be available for investors.
Read more →BVS▲ +7.4%on this news
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
Bioventus Inc. reported strong financial results for Q4 and full-year 2025, with a 2.8% increase in revenue and a significant profit turnaround. The company achieved a net income of $14.8 million in Q4, compared to a loss in the previous year. For 2026, Bioventus anticipates continued above-market revenue growth and robust cash generation, reflecting strong demand for its therapies.
Read more →BVSBioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
Bioventus Inc. will announce its financial results for the fourth quarter of fiscal year 2025 on March 5, 2026. The announcement will be made before market opening, followed by a conference call at 8:30 a.m. ET. This call will discuss the results and provide a business update, with a live webcast available for investors.
Read more →BVSBioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference
Bioventus Inc. will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Rob Claypoole is scheduled to deliver the presentation at 9:45 a.m. PT. The webcast will be accessible for a limited time on the company's investor website. Bioventus focuses on providing proven, cost-effective health solutions aimed at enhancing patient recovery and quality of life.
Read more →BVS▲ +5.1%on this news
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference
Bioventus Inc. has announced that its President and CEO, Rob Claypoole, will present at the Piper Sandler Healthcare Conference on December 3, 2025. This event will feature a live webcast of the presentation, along with a question-and-answer session. Bioventus specializes in clinically proven products aimed at promoting active healing across various therapies, including pain management and surgical solutions.
Read more →BVS▲ +15.1%on this news
Bioventus Reports Third Quarter Financial Results
Bioventus Inc. reported its financial results for Q3 2025, showcasing an 8.2% organic revenue growth despite a slight decline in reported revenue due to a previous divestiture. The company achieved a net income of $3.2 million, a significant improvement from a loss in the prior year. Adjusted EBITDA also rose by 12.9%, reflecting enhanced profitability and cash flow. However, international revenue faced a decline, highlighting some market challenges.
Read more →BVSBioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025
Bioventus Inc. will announce its financial results for Q3 of fiscal year 2025 on November 4, 2025. A conference call will be held at 8:30 a.m. ET to discuss these results and provide a business update. The call will be accessible via phone and a live webcast, which will also be archived for later access.
Read more →BVSBioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Bioventus Inc. has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. Mark Singleton, the company's Senior Vice-President and CFO, will engage in a fireside chat on September 10, 2025. The presentation will be available via live webcast and for replay on the company's website, emphasizing Bioventus's commitment to investor engagement.
Read more →BVSBioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
Bioventus Inc. will participate in the Canaccord Genuity 45th Annual Global Growth Conference on August 12, 2025. Rob Claypoole, the company's President and CEO, will engage in a fireside chat, followed by a Q&A session. A live webcast will be available on the company's website, ensuring accessibility for investors and stakeholders.
Read more →BVSBioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
Bioventus Inc. has secured a $400 million Senior Secured Credit Agreement, which includes a $300 million term loan and a $100 million revolving credit facility. This agreement, maturing in 2030, lowers the interest margin and increases liquidity significantly compared to previous arrangements. The funds will be used to repay existing debts, enhancing the company's financial position.
Read more →BVSBioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
Bioventus Inc. has received FDA 510(k) clearances for its TalisMann™ and StimTrial™ products, expanding its Peripheral Nerve Stimulation (PNS) offerings for chronic pain management. This development positions the company to capitalize on a rapidly growing PNS market, projected to exceed $500 million by 2029. A limited commercial release is expected in the third quarter of 2025, with broader rollout plans for early 2026.
Read more →BVSBioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
Bioventus Inc. has announced that it will report its financial results for the second quarter of fiscal year 2025 before market opening on August 6, 2025. A conference call will be held at 8:30 a.m. Eastern Time to discuss these results along with a business update. The company emphasizes its commitment to providing high-quality, evidence-based healing solutions, further highlighting its role in patient care and recovery.
Read more →About Bioventus Inc.
Headquarters4721 EMPEROR BOULEVARD, SUITE 100, DURHAM, NC, 27703
BIOPHARMAWATCH ELITE PLUS
Trade the next BVS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime